MET gene amplification has been described in gastric cancer (GC) and hepatocellular carcinoma (HCC), which results in dysregulation of MET signaling and is associated with clinical prognosis and poor outcome [6]. The gene discussed is MET; the disease is hepatocellular carcinoma.